- Home
- CDXS vs OTLK Comparison
CDXS vs OTLK Comparison
Compare CDXS & OTLK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CDXS | OTLK |
|---|---|---|
| Founded | 2002 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Chemicals | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 256.3M | 249.6M |
| IPO Year | 2008 | 2016 |
Fundamental Metrics
Financial Performance| Metric | CDXS | OTLK |
|---|---|---|
| Price | $2.47 | $1.44 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $2.50 |
| AVG Volume (30 Days) | 939.7K | ★ 15.2M |
| Earning Date | 05-07-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 43.82 | ★ 55.91 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $138,590,000.00 | $8,146,123.00 |
| Revenue This Year | $7.73 | $1,430.98 |
| Revenue Next Year | $14.24 | $173.23 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 32.30 | N/A |
| 52 Week Low | $0.96 | $0.16 |
| 52 Week High | $3.87 | $3.39 |
Technical Indicators
Market Signals| Indicator | CDXS | OTLK |
|---|---|---|
| Relative Strength Index (RSI) | 51.19 | 59.67 |
| Support Level | $2.41 | $0.26 |
| Resistance Level | $2.69 | $1.54 |
| Average True Range (ATR) | 0.15 | 0.23 |
| MACD | -0.00 | -0.03 |
| Stochastic Oscillator | 63.44 | 42.11 |
Price Performance
Historical ComparisonAbout CDXS Codexis Inc.
Codexis Inc is a biotechnology company engaged in providing enzyme-based technology solutions to improve pharmaceutical manufacturing processes. The company operates through two key business areas: the ECO Synthesis manufacturing platform and small molecule pharma biocatalysis. The ECO Synthesis platform focuses on developing enzymatic processes for the large-scale manufacture of RNA interference therapeutics, while the biocatalysis business utilizes engineered enzymes to enhance efficiency, yield, and sustainability in small molecule drug manufacturing. Geographically, it derives maximum revenue from the Americas.
About OTLK Outlook Therapeutics Inc.
Outlook Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing ONS-5010, a monoclonal antibody, or mAb, for various ophthalmic indications. The Company have received marketing authorization for an ophthalmic formulation of ONS-5010/LYTENAVA (bevacizumab-gamma) for use in treating wet age-related macular degeneration, or wet AMD, in the European Union, and United Kingdom. The product pipeline includes ONS-5010/LYTENAVA, which is in total eight NORSES; ONS-5010 Clinical Progress, Unmet Patient Needs, New Ophthalmic Anti-VEGF, and Potential First Line Therapy.